A Phase I safety trial started in 2015 in 42 healthy volunteers, but the results were never published
Some users experience nausea, vomiting, or gastrointestinal discomfort, especially during the initial adjustment period
This distinct mechanism amplifies the apoptotic cascade, even when protective proteins like Bcl-xL are present (175, 176)
Over the past decade, average out-of-pocket costs for obese individuals with employer coverage have increased by 37 percent, reaching $1,487 in 2021.[33] In comparison, individuals without obesity saw a 25 percent increase, averaging $698 per year
Effects are typically mild and dose-related, with subcutaneous administration sometimes causing local responses
It is important to note that even if insurance covers the drug, coverage may lapse after a set period